Donor CHIP and Allogeneic HSCT Outcome

Recruiting now

Conditions studied: Clonal Hematopoiesis

In brief

Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed to determine the association between donor gene mutations and outcome following allogeneic HSCT.

Key facts

Study ID

NCT04689750

Run by

The University of Hong Kong

People needed

850

Starts

2021-01-01

Expected to finish

2026-12-31

Last updated by the study team

2022-10-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult aged 18 year or above
• Donor and recipient of allo-HSCT
• In prospective and partial prospective/retrospective case, subjects who have provided a signed written informed consent. In retrospective case, subjects who had provided a previously signed written informed consent on:
• voluntary provision of clinical data, and
• voluntary provision of archived/remaining specimens for genetic analysis, and
• authorizing storage and usage of archived/remaining specimens for any further analysis

You may not qualify if…

• Autologous peripheral blood stem cells or bone marrow stem cell donors for autologous HSCT

Where it is running

• The University of Hong Kong — Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.